tbuckley/cabot-search huggingface dataset:
Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group
Authors: V. Heinemann, L. Fischer von Weikersthal, U. Vehling-Kaiser, M. Stauch, D. Oruzio, M. Schulze, H. G. Hass, J. Weiss, H. Dietzfelbinger, N. Moosmann
Journal: Journal of Clinical Oncology (2008)

4033 Background: Cetuximab combined with 5-fluorouracil/folinic acid (5-FU/FA) plus irinotecan or oxaliplatin has shown activity in the treatment of mCRC. This randomized trial compared the first-line efficacy of XELIRI plus cetuximab (XELIRI-C) to XELOX plus cetuximab (XELOX-C). Methods: Eligibility criteria: pts with untreated mCRC, Karnofsky performance status (KPS) >=70%, measurable lesions. Treatment plan: cetuximab 400 mg/m² was given iv on day 1 of cycle 1 and 250 mg/m² iv subsequently. In the XELIRI-C arm, pts received capecitabine (2 x 800 mg/m² po on days 1–14), and irinotecan (200 mg/m² iv on day 1) q3w. In pts >65 years doses of irinotecan and capecitabine were reduced by 20%. In the XELOX-C arm, capecitabine (2 x 1,000 mg/m2 po on days 1–14) was combined with oxaliplatin (130 mg/m² iv on day 1) q3w. The primary endpoint was the objective response rate (ORR) according to RECIST. Results: 185 pts were randomized to XELIRI-C (n=93) or XELOX-C (n=92). Median age (63 yrs vs 62 yrs), median KPS (90% vs 90%), and liver metastases (81% vs 88%) were well balanced. Pts received a median of 6 treatment cycles in both arms. In 142 evaluable pts (XELIRI-C vs XELOX-C: 74 vs 68) the ORR was 52.7% vs 61.8% and the disease control rate (CR+PR+SD) was 83.4% vs 97.1%, respectively. Median remission duration was 7.7 months vs 8.2 months, and median progression-free survival was 8.4 months (95% CI, 6.9–10.7 months) vs 9.2 months (95% CI, 8.1–11.2 months), respectively. Median overall survival has not yet been reached. The most common grade 3/4 CTC- toxicities observed in the XELIRI-C and the XELOX-C arm, respectively, were diarrhea (16.3% vs 20%), nausea (7.0% vs 9.4%), skin rash (12.8% vs 18.8%), hand-foot-syndrome (1.2% vs 2.4%), and sensory neuropathy (1.2% vs 12.9%). Conclusion: This randomized trial indicates efficacy and tolerability for cetuximab combined with XELIRI or XELOX as first-line treatment of mCRC. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Lilly Germany Lilly Germany Lilly Germany
Cas de tuberculose à bord d'un vol long courrier : les difficultés d'une investigation
Authors: A Vassiloyanakopoulos, G Spala, E Mavrou, C Hadjichristodoulou
Journal: Eurosurveillance (1999)

La transmission de Mycobacterium tuberculosis d'un passager a un autre lors d'un vol long courrier a ete rapportee en 1996 (1). D'autres cas avaient ete publies anterieurement, notamment par le CDC qui avait alors propose des criteres pour les enquetes a mener dans de telles circonstances (2). Plus recemment, en 1998, l'Organisation Mondiale de la Sante (OMS) a emis des recommandations pour de telles investigations, insistant sur la duree du vol (plus de huit heures), la contagiosite du patient index, et la proximite des sujets exposes (3).
Value of 18F-FDG PET/CT for Predicting the World Health Organization Malignant Grade of Thymic Epithelial Tumors
Authors: Seong Yong Park, Arthur Cho, Mi Kyung Bae, Chang Young Lee, Dae Joon Kim, Kyung Young Chung
Journal: Clinical Nuclear Medicine (2015)

Purpose We investigated whether preoperative parameters of 18F-FDG PET/CT were correlated with the World Health Organization (WHO) classification and/or Masaoka staging of thymic epithelial tumors. Patients and Methods We reviewed 61 patients retrospectively who were diagnosed with thymic epithelial tumors after surgical resection and PET/CT. A volume of interest was drawn on the primary lesion, using an SUV cutoff of 2.5, and metabolic indices such as SUVmax, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured. Results There were 24 male patients (38.7%), and the mean (SD) age was 50.23 (12.54) years. The mean (SD) tumor size was 6.11 (3.41) cm. There were 22 low-risk thymomas (36.9%) (A, AB, B1), 32 high-risk thymomas (51.6%), and 7 thymic carcinomas (11.5%). The Masaoka stage was I in 15 (24.6%), II in 30 (49.2%), III in 11 (18.0%), and IV in 5 patients (8.2%). Mean (SD) SUVmax was 3.43 (1.01) in low-risk thymomas, 4.42 (1.70) in high-risk thymomas, and 8.23 (2.61) in thymic carcinoma; the differences were significant (P < 0.001). Mean (SD) MTV and TLG were 90.74 (114.56) and 229.36 (300.56) in low-risk thymomas, 80.82 (112.49) and 233.93 (340.91) in high-risk thymomas, and 90.63 (90.74) and 390.94 (437.62), respectively, in thymic carcinomas. MTV and TLG showed no correlation with the WHO classification. On receiver operating characteristic curve analysis, the cutoff value for discriminating thymomas and thymic carcinomas was 5.05. SUVmax and TLG were correlated with Masaoka stage. Conclusions Although volume-dependent parameters were not correlated with the WHO classification, a significant relationship was observed between SUVmax and WHO classification and Masaoka stage.
Diverticulosis and Acute Diverticulitis of the Jejunum and Ileum
Authors: Francesco Michienzi, Orlando Pelliccia
Journal: New England Journal of Medicine (1959)

THE majority of authors writing about the subject agree on the rarity of diverticulosis affecting the jejunum and the ileum.It is the purpose of this paper to report 2 additional cases of pseudodiverticula of the jejunum and ileum, 1 manifesting as an acute surgical condition of the abdomen and the other as an incomplete small-bowel obstruction.Sir Astley Cooper1 wrote the original description, and Sir William Osler2 described 53 jejunal diverticula in a sixty-five-year-old patient as a post-mortem finding.In 1943 Benson, Dixon and Waugh3 accumulated over 300 cases and reported 122 cases of jejunoileal diverticula that were not . . .
Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine
Authors: Padhraig Gormley, Verneri Anttila, Bendik S Winsvold, Priit Palta, Tonu Esko, Tune H Pers, Kai-How Farh, Ester Cuenca-Leon, Mikko Muona, Nicholas A Furlotte, Tobias Kurth, Andres Ingason, George McMahon, Lannie Ligthart, Gisela M Terwindt, Mikko Kallela, Tobias M Freilinger, Caroline Ran, Scott G Gordon, Anine H Stam, Stacy Steinberg, Guntram Borck, Markku Koiranen, Lydia Quaye, Hieab H H Adams, Terho Lehtimäki, Antti-Pekka Sarin, Juho Wedenoja, David A Hinds, Julie E Buring, Markus Schürks, Paul M Ridker, Maria Gudlaug Hrafnsdottir, Hreinn Stefansson, Susan M Ring, Jouke-Jan Hottenga, Brenda W J H Penninx, Markus Färkkilä, Ville Artto, Mari Kaunisto, Salli Vepsäläinen, Rainer Malik, Andrew C Heath, Pamela A F Madden, Nicholas G Martin, Grant W Montgomery, Mitja I Kurki, Mart Kals, Reedik Mägi, Kalle Pärn, Eija Hämäläinen, Hailiang Huang, Andrea E Byrnes, Lude Franke, Jie Huang, Evie Stergiakouli, Phil H Lee, Cynthia Sandor, Caleb Webber, Zameel Cader, Bertram Muller-Myhsok, Stefan Schreiber, Thomas Meitinger, Johan G Eriksson, Veikko Salomaa, Kauko Heikkilä, Elizabeth Loehrer, Andre G Uitterlinden, Albert Hofman, Cornelia M van Duijn, Lynn Cherkas, Linda M Pedersen, Audun Stubhaug, Christopher S Nielsen, Minna Männikkö, Evelin Mihailov, Lili Milani, Hartmut Göbel, Ann-Louise Esserlind, Anne Francke Christensen, Thomas Folkmann Hansen, Thomas Werge, Jaakko Kaprio, Arpo J Aromaa, Olli Raitakari, M Arfan Ikram, Tim Spector, Marjo-Riitta Järvelin, Andres Metspalu, Christian Kubisch, David P Strachan, Michel D Ferrari, Andrea C Belin, Martin Dichgans, Maija Wessman, Arn M J M van den Maagdenberg, John-Anker Zwart, Dorret I Boomsma, George Davey Smith, Kari Stefansson, Nicholas Eriksson, Mark J Daly, Benjamin M Neale, Jes Olesen, Daniel I Chasman, Dale R Nyholt, Aarno Palotie
Journal: Nature Genetics (2016)
Epidemiologie du tetanos en Italie de 1971 a 2000
Authors: B Pedalino, B Cotter, M L Ciofi Degli Atti, D Mandolini, S Parroccini, S Salmaso
Journal: Eurosurveillance (2002)

L’incidence du tetanos en Italie a baisse de 0,5 cas pour 100 000 habitants dans les annees 1970 a 0,2/100 000 dans les annees 1990. Durant cette periode, le taux de letalite a diminue de 68% a 39%. L’Italie possede actuellement le plus grand nombre de ca
Case 3-1977
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Cecil H. Coggins, Robert T. McCluskey
Journal: New England Journal of Medicine (1977)

Presentation of CaseA nine-year-old girl was admitted to the hospital because of renal disease.She was born of a full-term, normal second pregnancy of a 29-year-old mother. Her birth weight was 1.9 kg (less than third percentile), and length 51 cm (50th percentile). Her early growth and development were normal. In recent years she had experienced frequent sore throats, often associated with the growth of beta-hemolytic streptococci on culture. Eight months before admission a routine physical examination disclosed no abnormality except that the blood pressure was 130/70 mm Hg. The urine give a ++ test for protein; the sediment . . .
UK science and health outside the EU
Authors: Anne Gulland
Journal: BMJ (2016)

Anne Gulland assesses the outlook for the NHS, drug industry, and public health 

NHS funding was one of the key battlegrounds of the referendum campaign. Prominent Brexit campaigners now seem to be rolling back on the pledges plastered on the side of their battle bus and on official posters that the £350m (€420m; $470m) a week they claimed the UK sends to Brussels should be spent on the NHS.

Conservative MP Iain Duncan Smith, member of the Vote Leave campaign, told the BBC after the result, “I never said that the £350m was an extrapolation of the £19.1bn—that’s the total amount of money we gave across to the European Union [in 2014]. What we actually said was a significant amount of it would go to the NHS.”

Researchers at the London School of Economics put the real weekly figure as £164m after taking into account the rebate and payments for areas such as agriculture and research. However, they write, “We would still not be able to reinvest all of the repatriated monies into our underfunded NHS as is often suggested. This money would be needed to negotiate trade deals, particularly if we want access to the single market . . . and to fund other areas which are currently heavily supported by EU contributions.” 1

Sarah Wollaston, Conservative chair of …
PD2-3-7: The antitumor effect caused by small molecular agents targeting EGFR, VEGFR2 and their downstream kinases in human non small cell lung cancer cells
Authors: Ichiro Nakachi, Katsuhiko Naoki, Kenzo Soejima, Ichiro Kawada, Hideo Watanabe, Hiroyuki Yasuda, Akitoshi Ishizaka
Journal: Journal of Thoracic Oncology (2007)
QOL-24VALIDATION STUDY OF THE JAPANESE VERSION OF M.D. ANDERSON SYMPTOM INVENTORY BRAIN TUMOR MODULE (MDASI-BT)
Authors: Shota Tanaka, Iori Sato, Masamichi Takahashi, Terri S. Armstrong, Charles S. Cleeland, Tito R. Mendoza, Akitake Mukasa, Yoshitaka Narita, Kiyoko Kamibeppu, Nobuhito Saito
Journal: Neuro-Oncology (2015)

BACKGROUND: It has been recognized that symptom burden reported as a patient-reported outcome is valuable in assessment of both disease and treatment-related symptoms and should be incorporated into evaluation of clinical benefit of novel therapies. MDASI-BT is a widely-used instrument for measuring symptom burden in brain tumor patients, and its Japanese version (MDASI-BT-J) has recently been validated linguistically. The purpose of this study is to psychometrically validate MDASI-BT-J. METHODS: Patients with brain tumors who were undergoing oncologic treatments in The University of Tokyo Hospital or National Cancer Center Hospital between 2014 and 2015 were asked to fill out MDASI-BT-J and the Japanese version of European Quality of Life-5 Dimensions (EQ-5D-J). Feasibility, reliability, and validity of MDASI-BT-J were assessed. RESULTS: One-hundred-and-forty patients (72 men) including 63 patients with gliomas participated in the study. The median age was 54 years, and the median Karnofsky Performance Status (KPS) score was 90. The mean symptom severity score (MSS) and mean interference score (MIS) were 1.9 ± 1.7 and 2.8 ± 2.7, respectively. The median amount of time required to complete the form was 4 minutes (range, 0-30), and missing values were seen in 1%. Internal consistency using Cronbach's coefficient alpha was 0.94 and 0.92 for symptom severity and interference, respectively. Test-retest reliability was assessed in 30 patients with acceptable intra-class correlation coefficient (mean, 0.74). Known-group validity confirmed a significant difference in MSS (1.6 versus 2.3, P = 0.007) and MIS (2.0 versus 3.9, P = 0.007) between patients with KPS score >= 90 and those with KPS score <90. As evidence of concurrent validity, EQ-5D-J correlated with MDASI-BT-J in the hypothesized magnitude and direction. CONCLUSIONS: The current study endorses reliability of the newly-developed MDASI-BT-J in evaluation of clinical benefit in brain tumor patients in Japan. It is being used as one of the secondary endpoints in a multi-center prospective study for newly-diagnosed glioblastoma.
Improvement in the Method for the Histochemical Demonstration of Alkaline Phosphatase and Its Use in a Study of Normal and Neoplastic Tissues&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Leon H. Manheimer, Arnold M. Seligman
Journal: JNCI Journal of the National Cancer Institute (1948)

Improvement in the Method for the Histochemical Demonstration of Alkaline Phosphatase and Its Use in a Study of Normal and Neoplastic Tissues Get access Leon H. Manheimer, Leon H. Manheimer Search for other works by this author on: Oxford Academic PubMed Google Scholar Arnold M. Seligman Arnold M. Seligman The Kirstein Laboratory for Surgical Research, Beth Israel Hospital, Boston, and the Department of Surgery, Harvard Medical School Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 9, Issue 3, December 1948, Pages 181–199, https://doi.org/10.1093/jnci/9.3.181 Published: 01 December 1948 Article history Received: 21 June 1948 Published: 01 December 1948
TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia
Authors: Russell E. Ware, Barry R Davis, William H Schultz, Clark Brown, Banu Aygun, Sharada A. Sarnaik, Isaac Odame, Beng Fuh, Alex George, William Owen, Lori Luchtman-Jones, Zora R. Rogers, Lee Hilliard, Cynthia Gauger, Connie M. Piccone, Margaret T. Lee, Janet Kwiatkowski, Sherron Jackson, Scott T. Miller, Carla W Roberts, Matthew M. Heeney, Theodosia A. Kalfa, Stephen C Nelson, Hamayun Imran, Kerri A Nottage, Ofelia A. Alvarez, Melissa Rhodes, Alexis A. Thompson, Jennifer Rothman, Kathleen J. Helton, Donna Roberts, Jamie Coleman, Melanie J Bonner, Abdullah Kutlar, Niren Patel, John C Wood, Linda Piller, Peng Wei, Judy Luden, Nicole A. Mortier, Susan Stuber, Naomi L.C. Luban, Alan R. Cohen, Sara L Pressel, Robert J. Adams
Journal: Blood (2015)
Training in Subspecialty Internal Medicine: On the Chessboard of Health Care Reform
Authors: Association of Subspecialty Professors
Journal: Annals of Internal Medicine (1994)

Many reform-minded observers of the U.S. health care system have asked recently whether we are training too many subspecialists in internal medicine. Of course, the answer to this question may not be the same for all subspecialties or all manners of professional career, but any proposed answer has extended consequences for the entire health care system and the patients it serves. Some have even begun to advocate a firm ceiling on the numbers of subspecialty training positions in the future. Who, in fact, should be deciding such matters? These decisions are complex and not easily made by government, consumers, or insurance companies on their own, nor should they. These decisions are best made by a profession willing to examine and regulate itself where necessary. Recent legislative initiatives have made it abundantly clear that others are more than willing to act on our behalf, if we cannot. Whatever process is adopted for making such decisions, it needs to be fair, efficient, flexible, and responsive to unexpected demands in the future, including new practice economics, the availability of research funds, and medical innovation.
Modeling Zika Virus Infection in Pregnancy
Authors: Indira U. Mysorekar, Michael S. Diamond
Journal: New England Journal of Medicine (2016)

There were few studies of Zika virus (ZIKV), a flavivirus, until this past year, when large epidemics in the Americas were accompanied by unexpectedly severe clinical manifestations. Infection in pregnant women has emerged as a major global concern because of its linkage to congenital abnormalities including microcephaly, spontaneous abortion, and intrauterine growth restriction.1 In addition, ZIKV infection in other age groups has been associated with severe neurologic disease and the Guillain–Barre syndrome.2 Transmission cycles between humans and Aedes aegypti mosquitoes in urban settings can cause large-scale epidemics of ZIKV infection. Although mosquitoes clearly are the primary cause of ZIKV outbreaks, . . .
Abstract 15796: Systemic Exposure of Porphyromonas Gingivalis Induces Early Cardiac Dysfunction Through Activation of Cytotoxic T-Cells
Authors: Kristine Y DeLeon-Pennell, Lisandra E de Castro Bras, Rugmani Padmanabhan Iyer, Elizabeth Flynn, Yu-Fang Jin, Merry L Lindsey
Journal: Circulation (2014)

Periodontal disease (PD) strongly correlates with increased mortality post-myocardial infarction (MI); however the cause is unknown. Circulating  Porphyromonas gingivalis  lipopolysaccharide ( Pg LPS) is present in over 50% of PD patients. Our previous studies revealed chronic  Pg LPS exposure increased systemic inflammation, which when superimposed on myocardial infarction (MI), increased and accelerated rupture of the left ventricle (LV), accelerated macrophage infiltration, and worsened cardiac function at day 7 (D7) post-MI. In this study, we hypothesized that circulating  Pg LPS increases the post-MI LV inflammatory response through activation of the adaptive immune response. We compared mice (4-6 months old; both sexes; n=6 survivors/group) infused with either  Pg LPS (0.08 μg/g/day) or saline starting at 28 days before and for the duration of MI. We used a permanent occlusion model of MI, and animals were sacrificed at D1 post-MI to examine the early inflammatory response. Proteomic profiling revealed increased levels of T-cell factors, namely interleukin (IL)-2, IL-12 and RANTES, in the LV of  Pg LPS exposed mice post-MI (p Pg LPS exposure increased T-cell infiltration (6%) compared to saline control (1%; p +  in the  Pg LPS group compared to 10% in the saline control (p Pg LPS exacerbated cytotoxic T-cell infiltration post-MI. Cytotoxic T-cells are activated through antigen presentation on major histocompatibility complex (MHC)-I. Post-MI, cytotoxic T-cells regulate macrophage infiltration through release of cytokines such as RANTES. To determine if cytotoxic T-cells were responsible for accelerated macrophage infiltration in  Pg LPS mice, MHC-I blocking antibody (MHCi, 0.2 μg/day) was given days before MI (21 days post- Pg LPS initiation). Galectin-3, a macrophage marker, dropped to levels comparable to saline controls at D1 post-MI in the MHCi group (p
The MicroRNA-183-96-182 Cluster Promotes T Helper 17 Cell Pathogenicity by Negatively Regulating Transcription Factor Foxo1 Expression
Authors: Kenji Ichiyama, Alicia Gonzalez-Martin, Byung-Seok Kim, Hyun Yong Jin, Wei Jin, Wei Xu, Mohsen Sabouri-Ghomi, Shunbin Xu, Pan Zheng, Changchun Xiao, Chen Dong
Journal: Immunity (2016)
Partial Gastrectomy: A Risk Factor for Pancreatic Cancer?
Authors: G. J. A. Offerhaus, M.D., Ph.D., A. C. Tersmette, M.P.H., F. M. Giardiello, M.D., G. W. Moore, M.D., Ph.D.
Journal: JNCI Journal of the National Cancer Institute (1986)

Journal Article Partial Gastrectomy: A Risk Factor for Pancreatic Cancer? Get access G. J. A. Offerhaus, M.D., Ph.D., G. J. A. Offerhaus, M.D., Ph.D. Department of Pathology, University Hospital Leiden, P.B. 9603, 2300 RC Leiden, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar A. C. Tersmette, M.P.H., A. C. Tersmette, M.P.H. Department of Pathology, University Hospital Leiden, P.B. 9603, 2300 RC Leiden, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar F. M. Giardiello, M.D., F. M. Giardiello, M.D. Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar G. W. Moore, M.D., Ph.D. G. W. Moore, M.D., Ph.D. Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 77, Issue 2, August 1986, Pages 591–592, https://doi.org/10.1093/jnci/77.2.591 Published: 01 August 1986
Phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients progressing after docetaxel treatment: Preliminary toxicity analysis—SOGUG-CABASEM trial.
Authors: Miguel Angel Climent Duran, Begoña Perez-Valderrama, Montserrat Domenech, Begoña Mellado, Ovidio Fernandez Calvo, Urbano Anido, Susana Hernando Polo, Jose Angel Arranz Arija, Eva Fernandez Parra, Cristina Caballero, Jose R. Germa-Lluch, Daniel E. Castellano
Journal: Journal of Clinical Oncology (2013)

e16014 Background: Docetaxel (D) is standard first-line chemotherapy in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). Cabazitaxel (C), a novel taxane developed to overcome D resistance, showed an overall survival improvement in second line CRPC in a three-weekly dose schedule. Its main toxicity is hematological with a risk of febrile neutropenia, especially in unfit patients. We aimed to evaluate efficacy and safety of weekly C/prednisone in "unfit" metastatic CRPC previously treated with D. Methods: Unfit pts (ECOG 2, dose reduction due to febrile neutropenia during treatment with D or radiation therapy affecting more than 25% of bone marrow reserve) with advanced CRPC progressing after D treatment with ECOG &lt;=2 and adequate bone marrow, liver and kidney functions were included. C 10 mg/m2 was administered on days 1, 8, 15 and 22 of 5-week cycles with daily prednisone 5 mg b.i.d. Radiological and PSA response was evaluated according to the PCCTWG II criteria and toxicity according NCI-CTC AE. Results: To date 28 pts have been enrolled and data are available for 21. Median age was 74 y (range 60-83), 13 (62%) pts had ECOG 2, 16 (76%) had bone metastases. Sixty-one cycles were administered (median: 3; range: 1-6) and 225 weekly administrations (median 10; range 1-24). Mean dose intensity was 94%. Most frequent related adverse events (AEs) of all grades as % of cycles were: asthenia (40%), anemia (34%), leukopenia (11%), thrombocytopenia (13%), diarrhea (10%), rash (8%), nauseas (8%), dysgeusia (8%), xerostomia (8%), anorexia (7%), mucositis (5%) and neuropathy (3%). Grade 3-4 AEs as % of cycles were: thrombocytopenia (8%), asthenia (7%), mucositis (2%), nausea (2%) and vomiting (2%). One patient discontinued the study due to asthenia G3. No grade III/IV diarrhea, neutropenia or febrile neutropenia were observed. Conclusions: Administration of weekly C (10 mg/m2) to unfit pts seems to be safe with no grade ≥3 neutropenia, diarrhea and febrile neutropenia reported. If confirmed in a larger scale, weekly C may represent an attractive option for unfit pts with mCRPC progressing after D treatment. Clinical trial information: NCT01518283.